GlassScriptPhysician profile
Steven B Newman
NPI 1750370755
$28,062.96
in general payments reported to CMS, 2019-2025
87 companies · $4,044 in 2025
The $4,044 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,095 · 2020: $3,078 · 2021: $4,113 · 2022: $4,576 · 2023: $4,561 · 2024: $4,597 · 2025: $4,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,639.01 |
| Education | $562.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,825.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,810.57 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Alexion Pharmaceuticals, INC. | $1,647.71 | 2019-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $1,632.60 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,423.57 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Celgene Corporation | $1,400.71 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $1,394.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,160.65 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Incyte Corporation | $934.69 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $889.75 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $886.70 | 2021-2025 | Libtayo |
| Genentech USA, INC. | $849.83 | 2019-2025 | Alecensa, Tecentriq, Polivy |
| Seagen INC. | $823.97 | 2020-2025 | Adcetris, Tukysa, Padcev |
| Genzyme Corporation | $810.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $710.49 | 2020-2025 | Ojjaara, Zejula, Shingrix |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $636.86 | 2020-2025 | |
| Eisai INC. | $594.94 | 2021-2025 | |
| Lilly USA, LLC | $589.18 | 2019-2025 | Verzenio, Jaypirca |
| Amgen INC. | $511.51 | 2019-2022 | |
| Beigene USA, INC. | $463.30 | 2020-2024 | Brukinsa |
| Astellas Pharma US INC | $448.17 | 2019-2025 | Xospata, Xtandi, Padcev |
| Daiichi Sankyo INC. | $407.58 | 2020-2025 | Enhertu, Datroway |
| Emd Serono, INC. | $344.67 | 2019-2025 | Bavencio |
| Alnylam Pharmaceuticals INC. | $332.69 | 2022-2023 | Onpattro, Givlaari |
| Sobi, INC | $324.86 | 2022-2025 | |
| Array Biopharma INC | $306.83 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $269.02 | 2019-2025 | |
| Kite Pharma, INC. | $245.57 | 2020-2024 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $231.56 | 2019-2023 | Epkinly, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $216.95 | 2021-2025 | Alunbrig, Ninlaro, Vpriv |
| Apellis Pharmaceuticals, INC. | $214.28 | 2023-2025 | Empaveli |
| Abbvie INC. | $211.42 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $191.33 | 2021-2025 | Myrisk |
| Sirtex Medical INC | $187.89 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $166.86 | 2019-2025 | Zepzelca |
| Motiva USA, LLC | $147.91 | 2024 | |
| Foundation Medicine, INC. | $143.73 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $134.24 | 2020-2024 | Qinlock |
| Morphosys, US INC. | $114.15 | 2021-2024 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.99 | 2019-2023 | Gilotrif |
| Pharmaessentia USA Corporation | $110.26 | 2022-2025 | Besremi |
| Tesaro, INC. | $103.50 | 2019 | |
| Cti Biopharma Corp. | $102.16 | 2022-2023 | Vonjo |
| Myovant Sciences INC. | $99.65 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $98.71 | 2019-2024 | Pyrukynd |
| Galvanize Therapeutics, INC | $94.63 | 2025 | Aliya System |
| Dova Pharmaceuticals | $87.72 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $87.16 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $86.39 | 2022-2025 | Onivyde |
| Taiho Oncology, INC. | $84.50 | 2023-2025 | |
| Kyowa Kirin, INC. | $82.34 | 2023-2025 | Poteligeo |
| Stemline Therapeutics INC. | $78.94 | 2023-2025 | Orserdu |
| Epizyme, INC. | $78.87 | 2021-2022 | |
| Adc Therapeutics America, INC. | $77.76 | 2022-2025 | |
| Acrotech Biopharma INC. | $77.27 | 2022-2024 | Beleodaq |
| Beone Medicines USA, INC. | $71.27 | 2025 | Brukinsa |
| Exelixis INC. | $65.54 | 2019-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $63.46 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $55.62 | 2020-2023 | Xarelto |
| Recordati_rare_diseases_inc. | $50.94 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $48.07 | 2021-2023 | Fotivda |
| Rigel Pharmaceuticals, INC. | $44.29 | 2020 | |
| Secura Bio, INC. | $40.37 | 2020-2021 | |
| Geron Corporation | $39.63 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $38.62 | 2024-2025 | Cosela, Monoferric |
| Karyopharm Therapeutics INC. | $35.05 | 2020 | |
| Thea Pharma INC. | $34.83 | 2025 | Iyuzeh |
| Amag Pharmaceuticals, INC. | $34.04 | 2022 | |
| Acceleron Pharma, INC. | $30.29 | 2020 | |
| Springworks Therapeutics, INC. | $28.84 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $26.03 | 2019 | |
| Janssen Scientific Affairs, LLC | $24.33 | 2019 | |
| Novo Nordisk INC | $24.18 | 2021 | |
| Coherus Oncology, INC. | $22.05 | 2022 | |
| G1 Therapeutics, INC. | $19.72 | 2023 | Cosela |
| Partner Therapeutics, INC. | $19.03 | 2019 | |
| Dendreon Pharmaceuticals LLC | $18.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.10 | 2020 | |
| Octapharma USA, INC. | $16.60 | 2023 | Octagam Immune Globulin (Human) |
| Aurobindo Pharma USA, INC. | $15.47 | 2019 | |
| Genmab U.S., INC. | $14.74 | 2025 | Epkinly |
| Emmaus Medical, INC. | $14.21 | 2021 | |
| Mirati Therapeutics, INC. | $13.49 | 2023 | Krazati |
| Verastem, INC. | $12.24 | 2019 | |
| Eusa Pharma (US) LLC | $11.54 | 2019 | |
| Shire North American Group INC | $11.09 | 2019 | |
| Veracyte, INC. | $2.07 | 2020 |
Drugs and devices associated with these payments
Keytruda $950Libtayo $700Opdivo $435Enhertu $422Trodelvy $385Pluvicto $357Stivarga $347Ojjaara $346Reblozyl $335Jakafi $324Lenvima $318Brukinsa $311Monjuvi $307Fabhalta $303Vitrakvi $299Ultomiris $292Nubeqa $276Imfinzi $262Rybrevant $248Verzenio $243Tukysa $223Opdualag $223Kisqali $221Adcetris $216Elrexfio $177Pemazyre $176Ibrance $166Padcev $166Jaypirca $160Vonjo $156Lynparza $155Xtandi $149Motiva Implant Matrix $148Darzalex $141Inlyta $139Pomalyst $138Onpattro $134Braftovi $134Erleada $127Lutathera $123Promacta $122Mektovi $122Piqray $120Sarclisa $119Empaveli $119Alunbrig $107Tecvayli $105Lorbrena $103Doptelet $103Talzenna $103Zepzelca $99.47Talvey $96.23Aliya System $94.63Venclexta $92.41Bosulif $89.90Scemblix $86.55Myrisk $85.66Lonsurf $84.50Inqovi $84.50Poteligeo $82.34Ninlaro $79.59Orserdu $78.94Alecensa $78.31Tecentriq $78.31Polivy $77.82Xospata $76.76Enjaymo $74.88Onivyde $68.69Xalkori $67.66Besremi $64.29Zejula $63.48Shingrix $61.96Gavreto $58.73Rozlytrek $58.73Avastin $58.73Yescarta $55.87Imbruvica $50.44Bavencio $49.88Zynyz $40.93Rytelo $39.63Cosela $39.50Xarelto $36.75Tivdak $36.08Nerlynx $35.51Iyuzeh $34.83Niktimvo $34.82Beleodaq $34.75Tabrecta $33.95Epkinly $33.04Calquence $32.85Pyrukynd $32.80Jevtana $30.34Jemperli $29.63Datroway $29.13Comirnaty $28.19Keytruda Qlex $26.57Gilotrif $25.66Cerdelga $24.22Cablivi $23.94Xofigo $23.76
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.